COMBINATION OF ONCOLYTIC VIRUSES WITH ANGIOGENESIS INHIBITORS

摘要

The invention relates to a combination therapy which comprises an tumour selective toxic virus and one or more therapeutic agents that reduce tumour blood vessel formation or damage tumour vasculature, especially for use in the treatment of neoplasms including solid tumours, metastases and other vascularised lesions. The therapeutic agent or agents may have additional antitumour effects, for example, as inhibitors of tumour cell proliferation via a cell cycle specific effect or via signal transduction inhibition. Preferred therapeutic agents are angiogenesis inhibitors including mTOR inhibitors, and vascular targeting agents. Tumour selective toxic viruses for use in the combination are replication competent viruses that have bee selected or designed to replicate preferentially in tumour cells and cause tumour cell killing.